葛兰素史克因2025年预计利润增长而上涨

2025-10-29 22:25

GSK (GSK) is up ~7% in Wednesday trading after reporting Q3 results that beat on both lines and updating its earnings growth projection for 2025.
The drugmaker now sees core earnings per share to increase 10%-12%, up from the top end of 6%-8% prior. Consensus is $4.34.
While revenue growth in Q3 was ~5% year over year, GSK benefitted in the third quarter from particularly strong sales in the following segments: Specialty Medicines £3.4B (+16%); Respiratory, Immunology & Inflammation £1.0B (+15%); Oncology £0.5B (+39%); and HIV £1.9B (+12%).
In its vaccines portfolio, Arexvy had the highest growth of 36% to £0.3B followed by Shingrix with growth of 13% to £0.8B.
General Medicines increased 4% to £2.5 billion, while sales of its asthma and COPD treatment Trelegy rose 25% to £0.7 billion.
In the quarter, non-GAAP EPS of £0.55 compares to £0.497 in the year-ago period.

More on GSK